BridgeBio Oncology
PublicBridgeBio Oncology is now publicly traded
The data on this page reflects BridgeBio Oncology's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
VC Round
May 2, 2024
Total Funding Raised
$200M
Company Overview
BridgeBio Oncology operates in Biotech and is based in South San Francisco, California. It has raised $200M.
BridgeBio Oncology Therapeutics is a biopharmaceutical company focused on developing small molecule therapeutics to treat genetic diseases and cancers, particularly targeting RAS and PI3K malignancies to enhance treatment outcomes for patients.
Sector
Biotech
AI Layer
Non-AI
BridgeBio Oncology Comparables
Compare BridgeBio Oncology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Quanta Therapeutics | 84% |
For institutional investors. Book with your work email.
BridgeBio Oncology Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BridgeBio Oncology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | VC Round |
| Enavate Sciences | VC Round |
| Deerfield Management | VC Round |
| Omega Funds | VC Round |
| GV | VC Round |
| Aisling Capital | VC Round |
| Citadel | VC Round |
For institutional investors. Book with your work email.
BridgeBio Oncology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.